The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...